Comparative pharmacology of the optical isomers of ketamine in mice☆
References (22)
- et al.
Stereoselective metabolism of amphetamine
Biochem. Pharmacol.
(1967) Stereochemical factors and receptor interactions associated with narcotic analgesics
J. Pharm. Sci.
(1966)- et al.
Nitrous oxide “analgesia”: resemblence to opiate action
Science
(1979) - et al.
Naloxone-induced inhibition of ethanol dependence in mice
Nature
(1977) - et al.
A gas chromatographic assay for ketamine in human plasma
Anesthesiology
(1972) - et al.
Intern. Anesth. Clin.
(1974) - et al.
Distribution in the brain and metabolism of ketamine in the rat after intravenous administration
Anesthesiology
(1973) - et al.
Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phenylcyclidine derivative CI-581
Anesth. Analg.
(1966) - et al.
Pharmacologic effects of CI-581, a new dissociative anesthetic, in man
Clin. Pharmacol. Therap.
(1965) - et al.
The metabolic fate of amphetamine in man and other species
Biochem. j.
(1970)
Intravenous Anesthesia
Cited by (152)
Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine
2023, NeuropharmacologyInjectable anesthetics
2023, Anesthesia and Analgesia in Laboratory AnimalsThe opioid system in depression
2022, Neuroscience and Biobehavioral ReviewsKetamine as a therapeutic agent for depression and pain: mechanisms and evidence
2022, Journal of the Neurological SciencesCitation Excerpt :Clinical trials of buprenorphine, a kappa-opioid receptor antagonist, demonstrate a rapid but transient anti-depressant effect (99). The analgesic effect of ketamine can be blocked by naloxone, an opioid receptor antagonist (100). Further in vitro studies found that ketamine bound to opioid receptors and displaced a radioactively labeled opioid receptor agonist (101).
Arylcyclohexamines
2021, Novel Psychoactive Substances: Classification, Pharmacology and ToxicologyComparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine
2019, Pharmacology Biochemistry and BehaviorCitation Excerpt :Due to its serious side effects, clinical use of ketamine has remained limited (Domino, 2010; Sanacora et al., 2017; Singh et al., 2017; Zhu et al., 2016), although it has been used as an off-label antidepressant in the USA (Reardon, 2018; Wilkinson et al., 2017). In this study, we found that locomotion after a single intranasal administration of (R)-ketamine is lower than those of (R,S)-ketamine and (S)-ketamine, consistent with the previous reports (Ryder et al., 1978; Yang et al., 2015) of subcutaneous or i.p. administration. Furthermore, we found that a single intranasal administration of (R)-ketamine did not cause PPI deficits in mice compared to (R,S)-ketamine and (S)-ketamine, consistent with the previous reports of i.p. administration (Yang et al., 2015).
- ☆
This is publication No. 77-25 from the Department of Pharmacology, University of California, San Francisco.
- ∗∗
This work represents partial fulfillment of the requirements for the degree of Doctor of Philosophy.